Your browser is no longer supported. Please, upgrade your browser.
Settings
IMGN ImmunoGen, Inc. daily Stock Chart
IMGN [NASD]
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-1.21 Insider Own0.10% Shs Outstand113.87M Perf Week-3.68%
Market Cap745.85M Forward P/E- EPS next Y-1.53 Insider Trans-25.29% Shs Float87.78M Perf Month-0.30%
Income-105.10M PEG- EPS next Q-0.20 Inst Own87.90% Short Float22.65% Perf Quarter8.09%
Sales89.00M P/S8.38 EPS this Y45.60% Inst Trans11.16% Short Ratio5.48 Perf Half Y81.44%
Book/sh-1.99 P/B- EPS next Y-106.80% ROA-54.20% Target Price9.50 Perf Year128.22%
Cash/sh1.32 P/C4.96 EPS next 5Y- ROE68.20% 52W Range1.51 - 8.84 Perf YTD221.08%
Dividend- P/FCF- EPS past 5Y1.00% ROI120.90% 52W High-25.90% Beta2.37
Dividend %- Quick Ratio2.30 Sales past 5Y5.60% Gross Margin- 52W Low333.77% ATR0.46
Employees308 Current Ratio2.40 Sales Q/Q427.00% Oper. Margin-96.10% RSI (14)45.15 Volatility4.44% 7.42%
OptionableYes Debt/Eq- EPS Q/Q80.70% Profit Margin- Rel Volume0.43 Prev Close6.50
ShortableYes LT Debt/Eq- EarningsOct 27 BMO Payout- Avg Volume3.63M Price6.55
Recom2.10 SMA20-8.62% SMA500.58% SMA20049.44% Volume1,553,023 Change0.77%
Jul-06-17Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $12
Apr-19-17Upgrade Leerink Partners Mkt Perform → Outperform
Apr-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $18 → $7
Feb-01-16Reiterated RBC Capital Mkts Outperform $19 → $18
Nov-25-15Upgrade Jefferies Hold → Buy
Sep-21-15Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-03-15Downgrade Cantor Fitzgerald Buy → Hold
Jul-29-15Reiterated Oppenheimer Outperform $13 → $24
Jul-27-15Reiterated RBC Capital Mkts Outperform $15 → $20
Jun-08-15Reiterated Leerink Partners Mkt Perform $9 → $15
Jun-01-15Upgrade Morgan Stanley Underweight → Equal-Weight
Jun-01-15Reiterated Canaccord Genuity Buy $15 → $20
Apr-27-15Reiterated Canaccord Genuity Buy $10 → $15
Mar-31-15Reiterated UBS Neutral $7 → $9
Feb-06-15Upgrade Oppenheimer Perform → Outperform $11
Dec-22-14Reiterated RBC Capital Mkts Outperform $18 → $11
Jun-12-14Upgrade UBS Sell → Neutral $8.50 → $13
Apr-16-14Initiated Canaccord Genuity Buy $20
Sep-30-13Initiated Chardan Capital Markets Buy $21
Aug-05-13Reiterated Cantor Fitzgerald Hold $13 → $14
Sep-22-17 08:14AM  ImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : September 22, 2017 Capital Cube
Sep-18-17 08:13PM  ImmunoGen Inc (IMGN): Risks You Need To Consider Before Buying Simply Wall St.
Sep-16-17 10:31AM  Is ImmunoGen Running Out of Steam, or Taking a Breather? Motley Fool
Sep-12-17 06:33PM  Why Shares of ImmunoGen, Inc. Sank Today Motley Fool -10.60%
Sep-07-17 04:35PM  Behind Jazzs Strategic Collaboration with ImmunoGen Market Realist
Sep-05-17 08:30AM  ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire -5.20%
04:00AM  Bull of the Day: Jazz Pharmaceuticals (JAZZ) Zacks
Sep-01-17 08:00AM  ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock Business Wire
Aug-31-17 06:54PM  ETFs with exposure to ImmunoGen, Inc. : August 31, 2017 Capital Cube
04:01PM  Biotechs On The Move Forbes
11:53AM  ImmunoGen (IMGN) Up 17.7% Since Earnings Report: Can It Continue? Zacks
07:50AM  Featured Company News - Jazz Pharma to Partner with ImmunoGen for the Development and Commercialization of Antibody-Drug Conjugate Products ACCESSWIRE
Aug-30-17 05:39PM  Why Investors Bid Immunogen Inc. Up Almost 12% Today Motley Fool +11.74%
12:00PM  Harry Boxers four biotech stocks to watch MarketWatch
11:47AM  Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule Zacks
08:56AM  ImmunoGen (IMGN) in Focus: Stock Moves 17.3% Higher Zacks
08:20AM  Today's Research Reports on Stocks to Watch: ImmunoGen, Inc. and Acorda Therapeutics Inc. ACCESSWIRE
Aug-29-17 04:21PM  Why Movado Group, Catalent, and ImmunoGen Jumped Today Motley Fool +17.34%
01:44PM  Why ImmunoGen, Inc. Jumped Higher Today Motley Fool
10:10AM  ImmunoGen and Jazz Enter Into Global Collaboration 24/7 Wall St.
10:10AM  Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers TheStreet.com
06:30AM  Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products Business Wire
Aug-25-17 10:50AM  ImmunoGen, Inc. :IMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-16-17 08:18AM  ImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : August 16, 2017 Capital Cube
Aug-15-17 08:00AM  ImmunoGen, Partnerships, Analyst Targets, Pipeline, and Guidance ACCESSWIRE +9.79%
Aug-12-17 11:21PM  Edited Transcript of IMGN earnings conference call or presentation 28-Jul-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-11-17 10:30PM  Edited Transcript of IMGN earnings conference call or presentation 5-May-17 12:00pm GMT Thomson Reuters StreetEvents +5.54%
Aug-04-17 08:59PM  ImmunoGen, Inc. Value Analysis (NASDAQ:IMGN) : August 5, 2017 Capital Cube
07:40AM  Featured Company News - Cytokinetics Announces Positive Results for Phase-2 Clinical Trial of Omecamtiv Mecabril in Japanese Patients with Heart Failure ACCESSWIRE
Aug-02-17 04:19PM  Here's What Pushed ImmunoGen, Inc. Stock 16.5% Lower in July Motley Fool
10:05AM  Penny Stocks to Watch for August 2017 Investopedia
Aug-01-17 04:30PM  ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference Business Wire
Jul-31-17 03:19PM  ImmunoGen, Inc. Earnings: What Goes Up, Must Come Down Motley Fool -14.66%
01:56PM  ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up Zacks
08:20AM  Today's Research Reports on Stocks to Watch: CytRx Corporation and ImmunoGen ACCESSWIRE
Jul-28-17 10:01PM  ImmunoGen reports 2Q loss Associated Press +14.29%
05:05PM  Why Shares of ImmunoGen Inc. Shot Up Today Motley Fool
12:43PM  Despite Decline in Global Markets, Several Stocks Are Jumping GuruFocus.com
07:34AM  ImmunoGen (IMGN) Reports Narrower-than-Expected Q2 Loss Zacks
06:30AM  ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results Business Wire
06:00AM  Investor Network: ImmunoGen, Inc. to Host Earnings Call ACCESSWIRE
Jul-25-17 04:25PM  Three biotech companies to watch ahead of earnings MarketWatch
Jul-24-17 04:16PM  Why ImmunoGen, Inc. Jumped Higher Today Motley Fool +12.01%
09:30AM  ImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : July 24, 2017 Capital Cube
Jul-21-17 11:45AM  Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings? Zacks
Jul-14-17 08:00AM  ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2017 Financial Results Business Wire
Jul-13-17 04:38PM  Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth? Zacks
Jul-10-17 01:19PM  Here's Why ImmunoGen, Inc. Shares Exploded 54% Higher in June Motley Fool
Jul-07-17 03:01PM  ETFs with exposure to ImmunoGen, Inc. : July 7, 2017 Capital Cube
Jun-26-17 07:57PM  Why ImmunoGen, Inc. Jumped Higher on Monday Motley Fool +12.54%
04:11PM  ETFs with exposure to ImmunoGen, Inc. : June 26, 2017 Capital Cube
08:00AM  ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia Business Wire
Jun-25-17 02:01PM  5 Best Biotech Stocks of 2017 So Far Motley Fool
Jun-22-17 08:00AM  Today's Research Reports on Stocks to Watch: Exact Sciences and Immunogen Accesswire
Jun-21-17 04:58PM  Why ImmunoGen, Inc. Jumped Higher for the Second Day in a Row Motley Fool +11.07%
02:58PM  Two Bullish Biotech Stocks And A Very Bearish Looking Yelp Forbes
08:50AM  ImmunoGen (IMGN) Jumps: Stock Rises 10.4% Zacks
Jun-20-17 07:31PM  Why ImmunoGen, Inc. Jumped Higher Today Motley Fool +10.39%
06:32PM  ImmunoGen Stock Nears Breakout to New Highs Investopedia
Jun-16-17 03:54PM  ETFs with exposure to ImmunoGen, Inc. : June 16, 2017 Capital Cube
Jun-15-17 03:00PM  Why Is ImmunoGen (IMGN) Stock Up 131% This Year? Zacks
Jun-14-17 09:14AM  ImmunoGen, Inc. :IMGN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-12-17 07:25AM  Short on Investing Cash? These $5 Stocks Are Up Big in 2017 Motley Fool
Jun-07-17 06:01AM  ImmunoGen (IMGN) Up 21.2% Since Earnings Report: Can It Continue? Zacks -5.23%
Jun-05-17 04:29PM  3 Stocks With Exelixis-Like Return Potential Motley Fool
May-30-17 12:55PM  ImmunoGen grabs $30M in reworked cancer drug pact with Sanofi American City Business Journals
08:30AM  ImmunoGen and Sanofi Amend License Agreements Business Wire
May-24-17 08:30AM  ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference Business Wire
May-23-17 04:01PM  Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen Business Wire
May-19-17 08:20AM  ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher Zacks
May-18-17 02:02PM  Why ImmunoGen, Inc. Jumped Higher Today Motley Fool +14.16%
May-17-17 05:00PM  ImmunoGen drug moving ahead in single-agent, combination trials Reuters
05:00PM  ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting Business Wire
May-15-17 03:56PM  Why ImmunoGen, Inc. Stock Is Flying High Today Motley Fool +11.22%
May-11-17 07:46AM  Edited Transcript of IMGN earnings conference call or presentation 5-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-10-17 02:58PM  ImmunoGen, Inc. Begins FORWARD I, Investors Wait Motley Fool
May-08-17 09:31AM  ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1 Zacks -9.83%
08:00AM  Today's Research Reports on Stocks to Watch: ImmunoGen and Ocular Therapeutix Accesswire
May-05-17 09:28AM  ImmunoGen (IMGN) Reports Narrower-than-Expected Loss Zacks
07:00AM  Investor Network: ImmunoGen, Inc. to Host Earnings Call Accesswire
06:35AM  ImmunoGen reports 1Q loss Associated Press
06:30AM  ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results Business Wire
May-04-17 08:38AM  Why ImmunoGen (IMGN) Might Surprise This Earnings Season Zacks
May-03-17 11:10AM  Here's Why ImmunoGen Rose 10.7% in April Motley Fool
May-02-17 10:16AM  Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season? Zacks
May-01-17 09:00AM  ImmunoGen Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer Business Wire
Apr-27-17 09:08AM  When Will ImmunoGen, Inc. Finally Start Making Money? Motley Fool
Apr-21-17 03:34PM  ImmunoGen, Inc. Value Analysis (NASDAQ:IMGN) : April 21, 2017 Capital Cube
08:30AM  ImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results Business Wire
Apr-20-17 04:43PM  Why ImmunoGen, Inc. Jumped Higher Today Motley Fool +17.04%
08:19AM  ImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : April 20, 2017 Capital Cube
Apr-19-17 12:38PM  Why ImmunoGen, Inc. Shot Up Today Motley Fool +10.49%
Apr-17-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Array Biopharma and ImmunoGen Accesswire
Apr-13-17 04:02PM  Why ImmunoGen, Inc. Stock Jumped Higher Today Motley Fool +9.46%
Mar-30-17 10:56AM  China's Creat Makes 1.2 Bln Euro Bid for German Blood Plasma Firm Investopedia
Mar-20-17 03:09AM  ImmunoGen (IMGN) Up 47.2% Since Earnings Report: Can It Continue? Zacks
Mar-16-17 09:30AM  TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention Accesswire
Mar-12-17 05:01PM  ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data at the Society of Gynecologic Oncology Annual Meeting Business Wire
Mar-09-17 01:04PM  IMMUNOGEN INC Financials +6.09%
08:24AM  Here's Why ImmunoGen, Inc. Skyrocketed 45% in February Motley Fool
ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARROWS CRAIGExecutive VP, General CounselSep 15Option Exercise4.5030,000135,00066,500Sep 15 03:51 PM
BARROWS CRAIGExecutive VP, General CounselSep 15Sale6.7322,450151,05344,050Sep 15 03:51 PM
BARROWS CRAIGExecutive VP, General CounselSep 13Option Exercise4.5020,00090,00051,100Sep 15 03:51 PM
BARROWS CRAIGExecutive VP, General CounselSep 13Sale6.9514,600101,40436,500Sep 15 03:51 PM
Berkenblit AnnaVP & Chief Medical OfficerSep 13Sale7.001,50010,500161,800Sep 18 11:16 AM
Goldberg Mark AlanDirectorDec 15Buy1.8020,00036,00023,800Dec 15 11:51 AM
Enyedy Mark JChief Executive OfficerNov 08Buy1.8325,00045,738100,100Nov 09 01:34 PM
LAMBERT JOHNExecutive Vice PresidentNov 02Buy1.692,7754,676120,521Nov 03 11:13 AM
Johnston David BrannonChief Financial OfficerNov 02Buy1.7010,00016,98110,000Nov 03 11:12 AM
Gregory Richard J.Executive VP & CSONov 02Buy1.7816,60029,59839,231Nov 03 12:55 PM
BARROWS CRAIGVice-President,General CounselNov 02Buy1.7110,00017,07531,100Nov 03 12:55 PM